Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part 1. Analysis of patients with fatal outcome during hospitalization
https://doi.org/10.52420/2071-5943-2022-21-5-58-66
Abstract
Introduction. Statins have a large number of pleiotropic effects, due to which they can be effective in cardiovascular complications of COVID-19. The aim of the study was to evaluate the relationship of regular statin intake with death and the development of new cardiovascular events in patients with cardiovascular pathology in the acute period of COVID-19. Materials and methods. A retrospective cohort study of patients diagnosed with COVID-19 with a history (before COVID-19) of cardiovascular pathologies, in which regular intake of lipid-lowering drugs is indicated, was conducted. Results. The study included 131 patients: 54 (41,22 %) people with a fatal outcome in the hospital; 77 (58,78 %) patients discharged from the infectious diseases hospital. During the period of hospitalization, 9 (16,67 %) cardiovascular events were documented in patients with a fatal outcome, more often in patients not taking statins, p = 0,399. The chance of death among hospitalized patients with COVID-19 with concomitant cardiovascular pathology is 2,62 times lower in patients taking statins, compared with patients who do not use these drugs for the treatment of cardiovascular diseases (OR 0,381; 95 % CI: 0,17–0,84), the differences are statistically significant (p = 0,015). Discussion. The beneficial effect of long-term statin intake observed in the acute period of COVID-19 is probably due to their additional protective effects: anti-inflammatory, antithrombotic, immunomodulatory and reducing endothelial dysfunction. Conclusions. Among patients with cardiovascular diseases hospitalized for COVID-19, only 1/3 takes the necessary lipid-lowering therapy. The use of statins before admission to the hospital and during treatment significantly reduces deaths in patients with cardiovascular pathology.
About the Authors
E. S. Klyachina
Ural State Medical University
Russian Federation
Russian Federation
Ekaterina S. Klyachina, Department assistant
Ekaterinburg
O. G. Smolenskaya
Ural State Medical University
Russian Federation
Russian Federation
Olga G. Smolenskaya, Doctor of Science (Medicine), Professor
Ekaterinburg
A. G. Makarochkin
Ural State Medical University
Russian Federation
Russian Federation
Andrej G. Makarochkin, Ph.D. in medicine
Ekaterinburg
S. S. Vedenskaya
Ural State Medical University
Russian Federation
Russian Federation
Svetlana S. Vedenskaya, Ph.D. in medicine
Ekaterinburg
References
1. Cummings M.J., Baldwin M.R., Abrams D. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. https://doi.org/10.1016/S0140-6736(20)31189-2.
2. Suleyman G., Fadel R.A., Malette K.M. et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020;3(6):e2012270. https://doi.org/10.1001/jamanetworkopen.2020.12270.
3. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. https://doi.org/10.1001/jama.2020.1585.
4. Li B., Yang J., Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. https://doi.org/10.1007/s00392-020-01626-9.
5. Bae S., Kim S.R., Kim M.N. et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis . Heart. 2021;107(5):373–380.
6. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. https://doi.org/10.1001/jama.2020.2648.
7. Baigent C., Blackwell L., Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5.
8. Montori V.M., Devereaux P.J., Adhikari N.K. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294(17):2203–2209. https://doi.org/10.1001/jama.294.17.2203.
9. Subir R., Jagat J.M., Kalyan K.G. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab Syndr. 2020;4(5):1225–1229. https://doi.org/10.1016/j.dsx.2020.07.011.
10. Oesterle A., Laufs U., Liao J.K. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229–243. https://doi.org/10.1161/CIRCRESAHA.116.308537.
11. Frost F.J., Petersen H., Tollestrup K., Skipper B. Influenza and COPD mortality protection as pleiotropic, dosedependent effects of statins. C hest. 2007;131(4):1006–1012. https://doi.org/10.1378/chest.06-1997.
12. Fedson D.S. A practical treatment for patients with Ebola virus disease. J Infect Dis. 2015;211(4):661–662. https://doi.org/10.1093/infdis/jiu474.
13. Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio. 2015;6(4):e01120. https://doi.org/10.1128/mBio.01120-15.
14. Zhang X.J., Qin J.J., Cheng X. et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176–187. https://doi.org/10.1016/j.cmet.2020.06.015.
15. Gupta A., Madhavan M.V., Poterucha T.J. et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):1325. https://doi.org/10.1038/s41467-021-21553-1.
16. Hognestad A., Dickstein K., Myhre E. et al. Effect of combined statin and beta–blocker treatment on one–year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol. 2004;93(5):603–606. https://doi.org/10.1016/j.amjcard.2003.11.027.
17. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
18. Chilimuri S., Sun H., Alemam A. et al. Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City. West J Emerg Med. 2020;21(4):779–784. https://doi.org/10.5811/westjem.2020.6.47919.
19. Шальнова С.А., Деев А.Д., Метельская В.А. с соавт. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2016;15(4):29–37.
Review
For citations:
Klyachina ES, Smolenskaya OG, Makarochkin AG, Vedenskaya SS. Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part 1. Analysis of patients with fatal outcome during hospitalization. Ural Medical Journal. 2022;21(5):58-66. (In Russ.) https://doi.org/10.52420/2071-5943-2022-21-5-58-66
Views:
205
Email this article 